Terms: = Kidney tumors AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Clinical Outcome
18 results:
1. The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and vegfr-TKIs.
Del Re M; Crucitta S; Paolieri F; Cucchiara F; Verzoni E; Bloise F; Ciampi R; Mercinelli C; Capuano A; Sportiello L; Martinetti A; Procopio G; Galli L; Porta C; Bracarda S; Danesi R
J Transl Med; 2022 Aug; 20(1):371. PubMed ID: 35974365
[TBL] [Abstract] [Full Text] [Related]
2. Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients.
Jiang W; Zeng H; Liu Z; Jin K; Hu B; Chang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
Urol Oncol; 2022 Apr; 40(4):166.e15-166.e25. PubMed ID: 34998671
[TBL] [Abstract] [Full Text] [Related]
3. A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma.
Sun J; Wang X; Tang B; Liu H; Zhang M; Wang Y; Ping F; Ding J; Shen A; Geng M
Theranostics; 2018; 8(12):3256-3267. PubMed ID: 29930727
[TBL] [Abstract] [Full Text] [Related]
4. A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients.
Schindler E; Amantea MA; Karlsson MO; Friberg LE
CPT Pharmacometrics Syst Pharmacol; 2017 Jun; 6(6):373-382. PubMed ID: 28378918
[TBL] [Abstract] [Full Text] [Related]
5. clinical outcome of high-dose bolus intravenous interleukin-2 with a modified administration schedule for Asian patients with metastatic renal cell carcinoma.
Lee JY; Song C; Hong BS; Hong JH; Ahn H; Lee JL
Cancer Chemother Pharmacol; 2017 Jan; 79(1):173-180. PubMed ID: 28011979
[TBL] [Abstract] [Full Text] [Related]
6. A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.
Stubbs C; Bardoli AD; Afshar M; Pirrie S; Miscoria M; Wheeley I; Porfiri E
Anticancer Res; 2017 Jan; 37(1):253-259. PubMed ID: 28011500
[TBL] [Abstract] [Full Text] [Related]
7. VEGF receptor subtypes may serve as novel prognostic factors and putative indicators for anti VEGF receptor treatment response in renal cell carcinoma cases.
Eronat O; Onursever A; Suren D; Yildirim M; Kandemir O; Ali Kahya H
J BUON; 2016; 21(5):1250-1258. PubMed ID: 27837630
[TBL] [Abstract] [Full Text] [Related]
8. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
Bianconi M; Faloppi L; Loretelli C; Zizzi A; Giampieri R; Bittoni A; Andrikou K; Del Prete M; Burattini L; Montironi R; Scartozzi M; Cascinu S
Oncotarget; 2016 Jun; 7(25):37599-37607. PubMed ID: 27175586
[TBL] [Abstract] [Full Text] [Related]
9. Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma.
Incorvaia L; Bronte G; Bazan V; Badalamenti G; Rizzo S; Pantuso G; Natoli C; Russo A
Oncotarget; 2016 Apr; 7(16):21259-71. PubMed ID: 26872372
[TBL] [Abstract] [Full Text] [Related]
10. [Three Patients with Acute Myocardial Infarction Associated with Targeted Therapy of Sorafenib for Metastatic Renal Cell Carcinoma : Case Report].
Takagi K; Takai M; Kawata K; Horie K; Kikuchi M; Kato T; Mizutani K; Seike K; Tsuchiya T; Yasuda M; Yokoi S; Nakano M; Ushikoshi H; Miyazaki T; Deguchi T
Hinyokika Kiyo; 2015 Sep; 61(9):347-51. PubMed ID: 26497860
[TBL] [Abstract] [Full Text] [Related]
11. Ca(2+) Signalling in Endothelial Progenitor Cells: Friend or Foe?
Moccia F; Guerra G
J Cell Physiol; 2016 Feb; 231(2):314-27. PubMed ID: 26247172
[TBL] [Abstract] [Full Text] [Related]
12. Analyses of Potential Predictive Markers and Response to Targeted Therapy in Patients with Advanced Clear-cell Renal Cell Carcinoma.
Song Y; Huang J; Shan L; Zhang HT
Chin Med J (Engl); 2015 Aug; 128(15):2026-33. PubMed ID: 26228213
[TBL] [Abstract] [Full Text] [Related]
13. EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.
Davis ID; Long A; Yip S; Espinoza D; Thompson JF; Kichenadasse G; Harrison M; Lowenthal RM; Pavlakis N; Azad A; Kannourakis G; Steer C; Goldstein D; Shapiro J; Harvie R; Jovanovic L; Hudson AL; Nelson CC; Stockler MR; Martin A
Ann Oncol; 2015 Jun; 26(6):1118-1123. PubMed ID: 25701452
[TBL] [Abstract] [Full Text] [Related]
14. Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy.
del Puerto-Nevado L; Rojo F; Zazo S; Caramés C; Rubio G; Vega R; Chamizo C; Casado V; Martínez-Useros J; Rincón R; Rodríguez-Remírez M; Borrero-Palacios A; Cristóbal I; Madoz-Gúrpide J; Aguilera O; García-Foncillas J
Br J Cancer; 2014 May; 110(11):2700-7. PubMed ID: 24786599
[TBL] [Abstract] [Full Text] [Related]
15. VEGF and vegfr polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.
Scartozzi M; Bianconi M; Faloppi L; Loretelli C; Bittoni A; Del Prete M; Giampieri R; Maccaroni E; Nicoletti S; Burattini L; Minardi D; Muzzonigro G; Montironi R; Cascinu S
Br J Cancer; 2013 Mar; 108(5):1126-32. PubMed ID: 23511629
[TBL] [Abstract] [Full Text] [Related]
16. Association of VEGF and vegfr2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.
Kim JJ; Vaziri SA; Rini BI; Elson P; Garcia JA; Wirka R; Dreicer R; Ganapathi MK; Ganapathi R
Cancer; 2012 Apr; 118(7):1946-54. PubMed ID: 21882181
[TBL] [Abstract] [Full Text] [Related]
17. Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action.
Larkin J; Swanton C; Pickering L
Expert Rev Anticancer Ther; 2011 Apr; 11(4):639-49. PubMed ID: 21504330
[TBL] [Abstract] [Full Text] [Related]
18. Levels of circulating CD45(dim)CD34(+)vegfr2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.
Farace F; Gross-Goupil M; Tournay E; Taylor M; Vimond N; Jacques N; Billiot F; Mauguen A; Hill C; Escudier B
Br J Cancer; 2011 Mar; 104(7):1144-50. PubMed ID: 21386843
[TBL] [Abstract] [Full Text] [Related]
